PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of ...

American Oncology Institute (AOI), a leading cancer hospital network in South Asia, successfully treated a 61-year-old ...

The American Oncology Institute (AOI) in Guntur has successfully treated a rare and complex case of Myasthenia Gravis ...

PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the ...

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development ...

AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine neoplasia type 1.

“Thymic carcinoma is a rare cancer with poor prognosis after recurrence, and there is a need for new treatment options. We are working to obtain approval so that Tecentriq that demonstrated favourable ...

while also helping prevent tumors from coming back. To make the therapy even ... May 13, 2025 — A new treatment approach significantly improves survival rates for patients with aggressive ...

Doctors classify lipomas as benign growths, or tumors, of fatty tissue. This means they’re not cancerous and rarely harmful. Still, if you notice a lump beneath your skin, you should see a ...

The tumor microenvironment influences the metabolic behavior of cancer cells. Here, using Dual Ribosome Profiling, the authors uncover a cancer-stromal cell interaction under glucose starvation ...

The objective of this paper is to evaluate available evidence for each step in autoimmune encephalitis management and provide expert opinion when evidence is lacking. The paper approaches autoimmune ...